Reports Q2 revenue $108.3M, consensus $104.8M. “In the second quarter, our global commercial efforts have resulted in continued meaningful growth of Crysvita, Dojolvi and Mepsevii revenue, including in our key territories outside of the U.S.,” said CEO Emil Kakkis. “At the same time, we have continued to advance key clinical programs for osteogenesis imperfecta (OI), Angelman syndrome and Wilson disease, which are expected to generate a number of data catalysts over the next few quarters.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
- 3 Best Stocks to Buy Now, 8/2/2023, According to Top Analysts
- Ultragenyx initiates dosing in second cohort of Phase 1/2/3 Cyprus2+ study
- Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
